Topotecan
Information
- Drug Name
- Topotecan
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| ovarian cancer | TOP1 EXPRESSION TOP1 EXPRESSION | B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 19648970 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Shorter progression free survival was observed in ... | TOP1 | TOP1 EXPRESSION TOP1 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| Topotecan: topoisomerase I inhibitor | BIRC5 | BIRC5 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02487095 | Active, not recruiting | Phase 1/Phase 2 | Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers | July 30, 2015 | October 30, 2025 |
| NCT04029688 | Active, not recruiting | Phase 1/Phase 2 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | January 27, 2020 | December 30, 2025 |
| NCT04209855 | Active, not recruiting | Phase 3 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | December 31, 2019 | April 2024 |
| NCT04908787 | Active, not recruiting | Phase 3 | A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer | June 11, 2021 | December 2024 |
| NCT02419495 | Active, not recruiting | Phase 1 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | June 26, 2015 | December 31, 2024 |
| NCT03600649 | Active, not recruiting | Phase 1 | Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | June 4, 2018 | December 2025 |
| NCT00657878 | Active, not recruiting | Phase 3 | Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval | November 2008 | December 2023 |
| NCT02308527 | Active, not recruiting | Phase 2 | Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children | July 2013 | February 2026 |
| NCT03709680 | Active, not recruiting | Phase 1/Phase 2 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | May 24, 2019 | February 25, 2025 |
| NCT04697628 | Active, not recruiting | Phase 3 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer | February 22, 2021 | August 5, 2025 |
| NCT03107988 | Active, not recruiting | Phase 1 | NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) | September 5, 2017 | December 2025 |
| NCT03786783 | Active, not recruiting | Phase 2 | Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | March 4, 2019 | September 22, 2024 |
| NCT03289910 | Active, not recruiting | Phase 2 | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | September 24, 2018 | December 21, 2024 |
| NCT02584478 | Active, not recruiting | Phase 3 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | December 2015 | December 2024 |
| NCT02502266 | Active, not recruiting | Phase 2/Phase 3 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | May 3, 2016 | June 30, 2024 |
| NCT02298348 | Active, not recruiting | Phase 1 | Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma | October 8, 2015 | December 2024 |
| NCT01783535 | Active, not recruiting | Phase 2 | Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma | June 19, 2013 | January 2028 |
| NCT01857934 | Active, not recruiting | Phase 2 | Therapy for Children With Advanced Stage Neuroblastoma | July 5, 2013 | December 2024 |
| NCT04106219 | Active, not recruiting | Phase 1 | A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | June 11, 2020 | August 25, 2024 |
| NCT02030964 | Active, not recruiting | Phase 1 | N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan | January 16, 2014 | December 30, 2024 |
| NCT02114229 | Active, not recruiting | Phase 2 | Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors | May 14, 2014 | September 2027 |
| NCT02101788 | Active, not recruiting | Phase 2/Phase 3 | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | February 27, 2014 | October 11, 2024 |
| NCT00193401 | Completed | Phase 2 | Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer | August 2002 | November 2004 |
| NCT00193570 | Completed | Phase 1 | Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors | February 2002 | January 2009 |
| NCT00193583 | Completed | Phase 1 | Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors | May 2003 | May 2005 |
| NCT00215956 | Completed | Phase 1 | A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma | November 2001 | January 2008 |
| NCT00257816 | Completed | Phase 2 | Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma | January 2004 | December 17, 2007 |
| NCT00259935 | Completed | Phase 1 | A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors | October 4, 2004 | July 5, 2007 |
| NCT00267488 | Completed | Phase 2 | Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer | October 2005 | December 2007 |
| NCT00276276 | Completed | Phase 3 | Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer | November 2000 | |
| NCT00294190 | Completed | Phase 2 | Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer | February 2006 | July 2009 |
| NCT00295243 | Completed | Phase 1 | Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies | September 2004 | November 2006 |
| NCT00305942 | Completed | Phase 2 | Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer | March 2006 | November 2009 |
| NCT00314678 | Completed | Phase 2 | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer | September 2005 | April 2007 |
| NCT00315861 | Completed | Phase 1 | Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies | March 2006 | January 2009 |
| NCT00316173 | Completed | Phase 2 | Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer | March 2005 | March 2009 |
| NCT00316186 | Completed | Phase 2 | First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin | June 2005 | May 2009 |
| NCT00317772 | Completed | Phase 1/Phase 2 | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | September 2, 2004 | November 4, 2020 |
| NCT00319969 | Completed | Phase 2 | Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. | April 2006 | January 2009 |
| NCT00001333 | Completed | Phase 1 | Phase I Study of Intrathecal Topotecan | February 1993 | December 2000 |
| NCT00322751 | Completed | Phase 1 | Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer | April 2006 | November 2009 |
| NCT00343044 | Completed | Phase 2 | Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | June 2006 | August 2011 |
| NCT00361803 | Completed | Phase 1 | Topotecan Pharmacokinetic Characterization Study | September 12, 2006 | August 9, 2007 |
| NCT00397293 | Completed | Phase 1/Phase 2 | Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer | November 2006 | December 2008 |
| NCT00436644 | Completed | Phase 2 | Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin | March 2007 | November 2012 |
| NCT00437307 | Completed | Phase 3 | Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse | March 2007 | June 2015 |
| NCT00460876 | Completed | Phase 1 | Phase I Trial of Periocular Topotecan in Retinoblastoma | March 2007 | April 2008 |
| NCT00466232 | Completed | Phase 1 | Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer | April 2007 | March 2010 |
| NCT00477282 | Completed | Phase 3 | Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer | August 2007 | June 2013 |
| NCT00483860 | Completed | Phase 1 | A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function | June 20, 2007 | February 6, 2012 |
| NCT00488709 | Completed | Phase 4 | Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 2003 | April 2007 |
| NCT00502892 | Completed | Phase 1 | Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors | August 2004 | January 2010 |
| NCT00516438 | Completed | Phase 1 | Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan | July 2007 | November 2009 |
| NCT00523432 | Completed | Phase 1 | A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies | August 2007 | December 2010 |
| NCT00547651 | Completed | Phase 3 | AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy | September 1, 2007 | May 1, 2011 |
| NCT00548418 | Completed | Phase 2 | Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer | February 2007 | December 2012 |
| NCT00553189 | Completed | Phase 1 | Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas | August 9, 2007 | September 28, 2011 |
| NCT00601003 | Completed | Phase 2 | Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma | January 14, 2008 | October 28, 2022 |
| NCT00611468 | Completed | Phase 1 | Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors | June 2006 | August 2009 |
| NCT00674674 | Completed | Phase 1 | Phase 1 Intrathecal Topotecan for Neoplastic Meningitis | October 2005 | December 2010 |
| NCT00703807 | Completed | Phase 1 | Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers | December 2008 | May 2010 |
| NCT00732420 | Completed | Phase 1 | Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors | September 24, 2008 | June 12, 2013 |
| NCT00744081 | Completed | Phase 2 | Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) | July 2004 | December 2010 |
| NCT00976911 | Completed | Phase 3 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | October 29, 2009 | July 9, 2014 |
| NCT01004874 | Completed | Phase 2 | Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma | December 30, 2009 | November 2, 2021 |
| NCT01037023 | Completed | Regulatory Hycamtin(Oral) PMS | October 2010 | November 2014 | |
| NCT01039025 | Completed | Phase 2 | TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma | February 18, 2002 | May 19, 2006 |
| NCT01121406 | Completed | Phase 2 | BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer | April 2010 | June 2014 |
| NCT01160185 | Completed | Meta-analysis of Efficacy of Topotecan | June 2009 | July 2009 | |
| NCT01345279 | Completed | Indirect Comparison Topotecan Cervical Carcinoma | June 2009 | July 2009 | |
| NCT01497873 | Completed | Phase 2 | A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer | September 2010 | March 2018 |
| NCT01500720 | Completed | Phase 2 | Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer | March 2012 | April 2014 |
| NCT01593228 | Completed | Phase 3 | Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial | May 2012 | September 2016 |
| NCT01630018 | Completed | Phase 2 | Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial | January 2011 | June 2014 |
| NCT01683149 | Completed | Phase 1 | Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies | January 2013 | January 2016 |
| NCT01690598 | Completed | Phase 1/Phase 2 | Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | November 2012 | February 2015 |
| NCT01931098 | Completed | Phase 2 | Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab | December 10, 2015 | September 12, 2019 |
| NCT00320983 | Completed | Phase 1 | Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer | March 2002 | December 2005 |
| NCT00001335 | Completed | Phase 2 | New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma | April 1993 | January 2002 |
| NCT00002395 | Completed | Phase 2 | Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML) | ||
| NCT00005792 | Completed | Phase 1 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | June 2, 1998 | November 1, 2018 |
| NCT00005793 | Completed | Phase 1/Phase 2 | A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide | July 1999 | November 2006 |
| NCT00038545 | Completed | Phase 2 | A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma | May 18, 2001 | April 27, 2004 |
| NCT00043862 | Completed | Phase 2 | The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) | August 2002 | |
| NCT00046111 | Completed | Phase 1 | A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors | September 2001 | April 2004 |
| NCT00049998 | Completed | Phase 3 | Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer | October 2001 | |
| NCT00057837 | Completed | Phase 2 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer | July 14, 2004 | August 2012 |
| NCT00061308 | Completed | Phase 2 | Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer | December 2002 | |
| NCT00100477 | Completed | Phase 2 | Use of Topotecan in Patients With Refractory Acute Leukemia | August 1998 | June 2001 |
| NCT00102375 | Completed | Phase 3 | Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer | December 1999 | October 2004 |
| NCT00117013 | Completed | Phase 1 | A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a | June 28, 2005 | October 25, 2010 |
| NCT00130858 | Completed | Phase 2 | a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4 | January 2005 | March 2009 |
| NCT00170677 | Completed | Phase 2 | Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer | September 2005 | January 2013 |
| NCT00179712 | Completed | Phase 1/Phase 2 | Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | April 2005 | November 2006 |
| NCT00189566 | Completed | Phase 2 | Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse | April 2004 | April 2009 |
| NCT00193167 | Completed | Phase 2 | Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer | January 2004 | April 2006 |
| NCT00193245 | Completed | Phase 2 | Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer | November 2000 | January 2009 |
| NCT00193297 | Completed | Phase 2 | Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma | February 2002 | June 2006 |
| NCT00193388 | Completed | Phase 2 | Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer | September 2002 | February 2007 |
| NCT02278510 | Completed | Early Phase 1 | Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma | December 9, 2014 | November 10, 2015 |
| NCT02390843 | Completed | Phase 1 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors | February 2015 | September 22, 2019 |
| NCT02421588 | Completed | Phase 3 | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients | May 2015 | October 12, 2018 |
| NCT02481830 | Completed | Phase 3 | Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer | September 14, 2015 | August 30, 2022 |
| NCT02566993 | Completed | Phase 3 | Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer | August 30, 2016 | February 24, 2020 |
| NCT02631876 | Completed | Phase 3 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | March 2, 2016 | January 2020 |
| NCT02786719 | Completed | N/A | High-Risk Neuroblastoma Chemotherapy Without G-CSF | June 2016 | February 5, 2019 |
| NCT02866006 | Completed | Phase 1/Phase 2 | Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer | October 2016 | June 2022 |
| NCT02903004 | Completed | Phase 3 | Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients | April 11, 2016 | December 20, 2018 |
| NCT03059667 | Completed | Phase 2 | Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | March 13, 2017 | December 1, 2020 |
| NCT03061812 | Completed | Phase 3 | Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) | April 11, 2017 | February 12, 2020 |
| NCT03088813 | Completed | Phase 3 | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer | April 25, 2018 | July 27, 2023 |
| NCT03098030 | Completed | Phase 2/Phase 3 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | June 1, 2017 | March 26, 2020 |
| NCT03154996 | Completed | Phase 1 | Chronic Convection Enhanced Delivery of Topotecan | January 18, 2018 | August 20, 2021 |
| NCT03367182 | Completed | Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer | September 1, 2017 | January 31, 2018 | |
| NCT04661852 | Completed | Phase 1 | Cabozantinib With Topotecan-Cyclophosphamide | December 23, 2020 | October 24, 2022 |
| NCT04768296 | Completed | Phase 2 | Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) | March 29, 2021 | July 21, 2023 |
| NCT05246111 | Completed | Phase 1 | Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208) | February 15, 2022 | June 28, 2023 |
| NCT06459180 | Not yet recruiting | Phase 3 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | July 5, 2024 | October 23, 2028 |
| NCT06203210 | Not yet recruiting | Phase 3 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | June 10, 2024 | February 22, 2029 |
| NCT06425419 | Not yet recruiting | Phase 1 | The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy | July 1, 2024 | March 1, 2026 |
| NCT05303727 | Not yet recruiting | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma | August 2022 | August 2027 |
| NCT06394492 | Not yet recruiting | Phase 3 | SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | May 31, 2024 | December 31, 2026 |
| NCT06128837 | Recruiting | Phase 3 | Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | March 3, 2024 | October 2028 |
| NCT04679064 | Recruiting | Phase 3 | Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment | December 1, 2020 | January 1, 2025 |
| NCT06161025 | Recruiting | Phase 2/Phase 3 | A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | February 27, 2024 | December 31, 2029 |
| NCT04799002 | Recruiting | Phase 3 | Topotecan and Melphalan for Retinoblastoma | March 11, 2021 | December 30, 2027 |
| NCT05092360 | Recruiting | Phase 3 | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) | January 10, 2022 | May 2027 |
| NCT04994977 | Recruiting | Phase 1 | Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery | May 4, 2023 | December 2026 |
| NCT04947501 | Recruiting | Early Phase 1 | A Study of N9 Chemotherapy in Children With Neuroblastoma | June 22, 2021 | June 22, 2025 |
| NCT05153239 | Recruiting | Phase 3 | Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | July 22, 2022 | April 2026 |
| NCT06172296 | Recruiting | Phase 3 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | April 19, 2024 | December 31, 2029 |
| NCT02813135 | Recruiting | Phase 1/Phase 2 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | August 3, 2016 | August 2027 |
| NCT05429502 | Recruiting | Phase 1/Phase 2 | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | December 27, 2022 | January 29, 2029 |
| NCT05870748 | Recruiting | Phase 2/Phase 3 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | July 12, 2023 | February 2026 |
| NCT03554473 | Recruiting | Phase 1/Phase 2 | M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers | September 11, 2018 | January 15, 2025 |
| NCT05613088 | Recruiting | Phase 2 | A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | February 1, 2023 | October 11, 2026 |
| NCT05874401 | Recruiting | Phase 4 | Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan | October 18, 2023 | July 30, 2027 |
| NCT05740566 | Recruiting | Phase 3 | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer | May 31, 2023 | August 1, 2027 |
| NCT05535166 | Recruiting | Phase 2 | Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma | December 20, 2022 | July 2035 |
| NCT05990738 | Recruiting | Phase 1 | DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan | January 15, 2024 | December 31, 2025 |
| NCT05800587 | Recruiting | Phase 2 | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | February 22, 2023 | August 1, 2029 |
| NCT06072781 | Recruiting | Phase 3 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | March 18, 2024 | February 9, 2031 |
| NCT05101551 | Recruiting | Phase 1 | Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy | February 23, 2023 | March 2026 |
| NCT04239092 | Recruiting | Phase 1 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | June 5, 2020 | December 2024 |
| NCT04322318 | Recruiting | Phase 2 | A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | October 19, 2020 | July 1, 2027 |
| NCT02354547 | Suspended | Phase 1 | A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors | December 2014 | December 2023 |
| NCT03927274 | Terminated | Early Phase 1 | Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma | June 20, 2019 | May 24, 2023 |
| NCT02684071 | Terminated | Phase 2 | Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors | February 2016 | December 9, 2019 |
| NCT02963090 | Terminated | Phase 2 | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | May 20, 2017 | August 20, 2019 |
| NCT00720096 | Terminated | N/A | Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan | July 2008 | October 2009 |
| NCT03165292 | Terminated | Phase 2 | Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction | October 1, 2018 | March 28, 2024 |
| NCT00526799 | Terminated | Phase 1/Phase 2 | Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer | September 2007 | August 2010 |
| NCT00437073 | Terminated | Phase 2 | Brain Metastases In ErbB2-Positive Breast Cancer | May 2007 | February 2010 |
| NCT00322920 | Terminated | Phase 1 | Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer | July 2005 | |
| NCT02649673 | Terminated | Phase 1 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies | March 23, 2016 | July 30, 2021 |
| NCT04022876 | Terminated | Phase 1 | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | September 3, 2019 | August 30, 2022 |
| NCT00313612 | Terminated | Phase 2 | Oxaliplatin and Topotecan in Advance Ovarian Cancer | January 2006 | December 2012 |
| NCT00194935 | Terminated | Phase 2 | Weekly Topotecan Therapy in Patients With Ovarian Cancer | February 2003 | August 2006 |
| NCT04455139 | Terminated | Phase 2 | A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma | November 15, 2021 | May 22, 2023 |
| NCT00158886 | Terminated | Phase 1 | Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer | November 8, 2001 | August 11, 2006 |
| NCT02100007 | Terminated | Phase 1/Phase 2 | ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors | April 2014 | April 2016 |
| NCT01177501 | Terminated | Phase 1 | Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma | April 2009 | March 2012 |
| NCT01076400 | Terminated | Phase 1/Phase 2 | A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008) | May 31, 2010 | June 13, 2011 |
| NCT01003938 | Terminated | Phase 2 | Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer | August 2009 | December 2012 |
| NCT02500459 | Terminated | Early Phase 1 | Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection | July 6, 2015 | November 19, 2018 |
| NCT00888810 | Terminated | Phase 2 | Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer | March 2008 | |
| NCT02514447 | Terminated | Phase 1/Phase 2 | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy | October 5, 2015 | October 4, 2021 |
| NCT00808899 | Terminated | Phase 2 | Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma | December 2008 | July 2009 |
| NCT02980809 | Unknown status | Phase 2 | Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer | March 2017 | March 2020 |
| NCT02200757 | Unknown status | Phase 2 | Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer | September 2014 | July 2017 |
| NCT04073550 | Unknown status | Phase 3 | Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer | October 31, 2019 | July 31, 2022 |
| NCT03763123 | Unknown status | Phase 1 | A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer. | April 24, 2018 | December 31, 2020 |
| NCT00502762 | Unknown status | Phase 2 | Topotecan for Irinotecan-Refractory SCLC | September 2004 | August 2007 |
| NCT02738346 | Unknown status | Phase 3 | SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013 | July 2013 | July 2017 |
| NCT03227016 | Unknown status | Phase 1 | Study in Patients With SCLC of Veliparib in Combination With Topotecan | October 2016 | June 2021 |
| NCT02866370 | Unknown status | Phase 2 | Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium | April 2015 | March 2021 |
| NCT05083000 | Unknown status | Phase 1 | Reducing Hypoxia in Patients With Coronavirus Disease (COVID-19) Using Topotecan With Standard of Care | August 16, 2021 | March 31, 2022 |
| NCT00006199 | Unknown status | Phase 1 | Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32) | ||
| NCT04213937 | Unknown status | Phase 2 | Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer | January 31, 2020 | January 31, 2022 |
| NCT00308165 | Unknown status | Phase 1/Phase 2 | Safety Study of Intracerebral Topotecan for Recurrent Brain Tumors | March 2004 | December 2015 |
| NCT04943627 | Withdrawn | Phase 3 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | August 2, 2021 | October 22, 2021 |
| NCT02348398 | Withdrawn | Phase 2 | Phase II Study of Pazopanib and Topotecan in Cervical Cancer | August 2016 | |
| NCT01736800 | Withdrawn | Phase 2 | Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors | March 2007 | November 2014 |